Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Zorifertinib - AstraZeneca

Next Previous
Drug Profile

Zorifertinib - AstraZeneca

Alternative Names: AZD-3759; EGFR antagonist - AstraZeneca; Epidermal growth factor receptor tyrosine kinase inhibitor - AstraZeneca

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator AstraZeneca
  • Developer Alpha Biopharma; AstraZeneca
  • Class Amines; Antineoplastics; Piperazines; Quinazolines; Small molecules
  • Mechanism of Action Epidermal growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Non-small cell lung cancer

Most Recent Events

  • 05 Jun 2023 Efficacy and adverse events data from phase II/III trial in Non-small cell lung cancer presented at the 59th Annual Meeting of the American Society of Clinical Oncology (ASCO-2023)
  • 29 Jan 2023 The NMPA accepts NDA for Zorifertinib for Non-small cell lung cancer (First-line therapy, Late-stage disease) (PO) for review
  • 29 Jan 2023 Preregistration for Non-small cell lung cancer (First-line therapy, Late-stage disease) in China (PO) , before January 2023
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top